267 related articles for article (PubMed ID: 10830299)
1. Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers.
Rekasi Z; Varga JL; Schally AV; Halmos G; Armatis P; Groot K; Czompoly T
Endocrinology; 2000 Jun; 141(6):2120-8. PubMed ID: 10830299
[TBL] [Abstract][Full Text] [Related]
2. Antagonistic actions of analogs related to growth hormone-releasing hormone (GHRH) on receptors for GHRH and vasoactive intestinal peptide on rat pituitary and pineal cells in vitro.
Rekasi Z; Varga JL; Schally AV; Halmos G; Groot K; Czompoly T
Proc Natl Acad Sci U S A; 2000 Feb; 97(3):1218-23. PubMed ID: 10655511
[TBL] [Abstract][Full Text] [Related]
3. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
Rekasi Z; Schally AV; Plonowski A; Czompoly T; Csernus B; Varga JL
Prostate; 2001 Aug; 48(3):188-99. PubMed ID: 11494334
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity.
Plonowski A; Varga JL; Schally AV; Krupa M; Groot K; Halmos G
Int J Cancer; 2002 Apr; 98(4):624-9. PubMed ID: 11920625
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor.
Plonowski A; Schally AV; Letsch M; Krupa M; Hebert F; Busto R; Groot K; Varga JL
Prostate; 2002 Aug; 52(3):173-82. PubMed ID: 12111694
[TBL] [Abstract][Full Text] [Related]
6. Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer.
Halmos G; Schally AV; Czompoly T; Krupa M; Varga JL; Rekasi Z
J Clin Endocrinol Metab; 2002 Oct; 87(10):4707-14. PubMed ID: 12364462
[TBL] [Abstract][Full Text] [Related]
7. Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone.
Sotomayor S; Carmena MJ; Schally AV; Varga JL; Sánchez-Chapado M; Prieto JC; Bajo AM
Int J Oncol; 2007 Nov; 31(5):1223-30. PubMed ID: 17912451
[TBL] [Abstract][Full Text] [Related]
8. Antagonistic analogs of growth hormone releasing hormone (GHRH) inhibit cyclic AMP production of human cancer cell lines in vitro.
Csernus V; Schally AV; Groot K
Peptides; 1999; 20(7):843-50. PubMed ID: 10477085
[TBL] [Abstract][Full Text] [Related]
9. Antiproliferative actions of growth hormone-releasing hormone antagonists on MiaPaCa-2 human pancreatic cancer cells involve cAMP independent pathways.
Rekasi Z; Varga JL; Schally AV; Plonowski A; Halmos G; Csernus B; Armatis P; Groot K
Peptides; 2001 Jun; 22(6):879-86. PubMed ID: 11390017
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer.
Muñoz-Moreno L; Arenas MI; Schally AV; Fernández-Martínez AB; Zarka E; González-Santander M; Carmena MJ; Vacas E; Prieto JC; Bajo AM
Int J Cancer; 2013 Feb; 132(4):755-65. PubMed ID: 22777643
[TBL] [Abstract][Full Text] [Related]
11. Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone.
Halmos G; Schally AV; Varga JL; Plonowski A; Rekasi Z; Czompoly T
Proc Natl Acad Sci U S A; 2000 Sep; 97(19):10555-60. PubMed ID: 10962030
[TBL] [Abstract][Full Text] [Related]
12. Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers.
Letsch M; Schally AV; Busto R; Bajo AM; Varga JL
Proc Natl Acad Sci U S A; 2003 Feb; 100(3):1250-5. PubMed ID: 12538852
[TBL] [Abstract][Full Text] [Related]
13. Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers.
Rekasi Z; Czompoly T; Schally AV; Halmos G
Proc Natl Acad Sci U S A; 2000 Sep; 97(19):10561-6. PubMed ID: 10962031
[TBL] [Abstract][Full Text] [Related]
14. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.
Heinrich E; Schally AV; Buchholz S; Rick FG; Halmos G; Mile M; Groot K; Hohla F; Zarandi M; Varga JL
Prostate; 2008 Dec; 68(16):1763-72. PubMed ID: 18729085
[TBL] [Abstract][Full Text] [Related]
15. Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities.
Zarandi M; Varga JL; Schally AV; Horvath JE; Toller GL; Kovacs M; Letsch M; Groot K; Armatis P; Halmos G
Proc Natl Acad Sci U S A; 2006 Mar; 103(12):4610-5. PubMed ID: 16537407
[TBL] [Abstract][Full Text] [Related]
16. Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice.
Chatzistamou I; Schally AV; Varga JL; Groot K; Armatis P; Busto R; Halmos G
J Clin Endocrinol Metab; 2001 May; 86(5):2144-52. PubMed ID: 11344219
[TBL] [Abstract][Full Text] [Related]
17. Vasoactive intestinal polypeptide receptor VPAC(1) subtype is predominant in rat prostate membranes.
Juarranz MG; De Neef P; Robberecht P
Prostate; 1999 Sep; 41(1):1-6. PubMed ID: 10440869
[TBL] [Abstract][Full Text] [Related]
18. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
[TBL] [Abstract][Full Text] [Related]
19. Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog.
Collado B; Carmena MJ; Sánchez-Chapado M; Ruíz-Villaespesa A; Bajo AM; Fernández-Martínez AB; Varga JL; Schally AV; Prieto JC
Int J Oncol; 2005 Jun; 26(6):1629-35. PubMed ID: 15870879
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of growth and reduction in tumorigenicity of UCI-107 ovarian cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
Chatzistamou I; Schally AV; Varga JL; Groot K; Armatis P; Bajo AM
J Cancer Res Clin Oncol; 2001 Nov; 127(11):645-52. PubMed ID: 11710593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
